News & Updates

In a national cohort study in Singapore, a booster dose of BNT162b2 maintained individual protection against severe COVID-19 disease among adolescents aged 12–17 years.

In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.

For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.

In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.

Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.